Lorenz Studer News Today

Slow maturation of neurons in our brains and nervous systems presents a hindrance in laboratory research.

The neurons that make up our brains and nervous systems mature slowly over many months.

The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.

Early Career Group Leaders for the Institute of Human Biology (IHB) in Full time, Head of Department, Biomedicine with Adveritas - F. Hoffmann la Roche. Apply Today.

/PRNewswire/ -- Magdalena Zernicka-Goetz, PhD, was announced today as the recipient of the 2023 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....

/PRNewswire/ -- Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....

/PRNewswire/ -- Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....

Share Projects funded by the New York State Stem Cell Science program included ones studying human embryonic stem cells (center). Science Source New York state ends stem cell research funding Apr. 16, 2021 , 3:45 PM Over the past decade, New York state has become an international hub of stem cell research. In part, that’s thanks to one of the United States’s only state-level programs devoted exclusively to this area of science, researchers say. But now, New York’s state government...

16 Feb 2021 In the brain, complex interactions between different cell types can drive inflammation and disease. This cross talk is hard to study in vitro, because culture systems are often too simple to recapitulate the intricacies of the brain, or the mix of cells is too poorly defined to give reliable results. In the February 8 Nature Neuroscience, researchers led by Lorenz Studer at the Sloan Kettering Institute for Cancer Research in New York City describe a triculture system of neurons, mi...

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinsons Disease News provided by Share this article Share this article CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleare...